Sanjivani Paranteral Ltd.

69.24 +3.00 ▲4.5%

05 June 2023, 11:07:00 AM
Volume: 33,929

Company Profile

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.sanjivani.co.in
Market Cap 66.23 Cr.
Enterprise Value(EV) 68.72 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 4.51 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 14.68 Trailing Twelve Months Ending 2023-03
Industry PE 33.43 Trailing Twelve Months Ending 2023-03
Book Value / Share -3.07 Trailing Twelve Months Ending 2023-03
Price to Book Value -21.55 Calculated using Price: 66.24
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 1.00 Cr. 9,998,300 Shares
FaceValue 10
About Sanjivani Paranteral Ltd.
Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company's products includes oral solids, small volume parenterals and sterile powder formulations.

Sanjivani Paranteral Ltd. Delivery

Delivered Qty
Traded Qty

Sanjivani Paranteral Ltd. Performance

1 Day
+4.53%
1 Week
+15.40%
1 Month
+25.87%
3 Month
+102.93%
6 Month
+71.17%
1 Year
+31.26%
2 Year
+518.21%
5 Year
+1054.00%
10 Year
+317.11%

Sanjivani Paranteral Ltd. Fundamental Ratios

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 4.66 -7.19 -58.98 -596.93
Return on Capital Employed (%) 12.18 5.69 -7.28 -33.04 -227.28 -265.98 266.43
Return on Assets (%) 1.38 -2.09 -14.16 -34.18 -124.34 -9.62 -10.16 8.13 25.80

Sanjivani Paranteral Ltd. Balance Sheet

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds 35 32 18 -9 -53 -47 -49 -45 -8 -3
Non Curr. Liab. 8 7 14 9 6 10 9 7 4 1
Curr. Liab. 74 75 62 61 72 56 55 58 22 23
Minority Int.
Equity & Liab. 117 114 93 60 25 18 16 19 18 21
Non Curr. Assets 27 16 23 17 16 11 12 10 11 13
Curr. Assets 90 98 70 43 9 7 4 9 8 8
Misc. Exp. not W/O
Total Assets 117 114 93 60 25 18 16 19 18 21

Sanjivani Paranteral Ltd. Profit and Loss

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 159 133 115 33 18 25 16 25 31 35
Other Income 3 1 1 3 0 1 0 0 2 1
Total Income 161 135 116 36 18 26 17 25 32 36
Total Expenditure -149 -128 -121 -56 -70 -27 -17 -23 -26 -30
PBIDT 12 7 -5 -20 -52 -1 0 2 6 6
Interest -8 -8 -9 -5 0 0 -1 0 0 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Taxation -1 0 0 0 0 0 0 0 0 0
Exceptional Items 0
PAT 2 -2 -15 -26 -53 -2 -2 1 5 5
Adjusted EPS 3 -4 -25 -44 -90 -4 -3 2 5 5

Sanjivani Paranteral Ltd. Cash Flow

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 7 9 -1 0 10 3 2 0 1 9
Cash Fr. Inv. -1 -1 9 -1 0 0 0 0 0 -1
Cash Fr. Finan. -6 -8 -7 -1 -10 -3 -2 0 0 -8
Net Change 0 0 0 -1 0 0 0 0 0 0
Cash & Cash Eqvt 1 1 1 0 0 0 0 0 0

Sanjivani Paranteral Ltd. Shareholding Pattern

9 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 24.63 24.63 19.85 27.35 27.35 27.35 27.35 27.35 29.88
Public 75.37 75.37 80.15 72.65 72.65 72.65 72.65 72.65 70.12
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Sanjivani Paranteral Ltd. Announcements

Sat, 03 Jun 2023
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ashwani Khemka & Naina Khemka
Fri, 02 Jun 2023
Intimation To Exchange As Per Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 And Regulation 7 (2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015
Company has received disclosure from the following shareholders regarding acquisition of the Shares of the Company : 01. Ashwani Khemka
Wed, 31 May 2023
Intimation To Exchange As Per Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 And Regulation 7 (2) Of SEBI (Prohibition Of Insider Trading) Regulations 2015
Company has received disclosure from the following shareholders regarding acquisition of the Shares of the Company : 01. Ashwani Khemka

Sanjivani Paranteral Ltd. Technical Scans

Fri, 02 Jun 2023
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Closing Above Previous High Closing Above Previous High
Making Higher Highs for 3 days Making Higher Highs for 3 days

Sanjivani Paranteral Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 239,777.54 1,012.15 +1.3%
Divi's Laboratories Ltd. 93,340.08 3,470.45 -1.2%
Cipla Ltd. 77,917.34 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. 76,753.53 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. 71,422.15 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. 60,134.99 1,782.90 +0.3%
Mankind Pharma Ltd. 58,728.27 1,438.50 -1.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 28.30 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 51.54 3,470.45 -1.2%
Cipla Ltd. Consolidated 2023-03 27.85 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 17.03 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 87.03 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 48.23 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 43.99 1,438.50 -1.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.28 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2023-03 7.36 3,470.45 -1.2%
Cipla Ltd. Consolidated 2023-03 3.33 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.30 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 11.52 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9.69 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 5.65 1,438.50 -1.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,470.45 -1.2%
Cipla Ltd. Consolidated 2022-03 0.04 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 0.14 1,438.50 -1.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,470.45 -1.2%
Cipla Ltd. Consolidated 2022-03 13.10 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,438.50 -1.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,470.45 -1.2%
Cipla Ltd. Consolidated 2022-03 13.10 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,438.50 -1.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,470.45 -1.2%
Cipla Ltd. Consolidated 2022-03 21,763.34 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 7,781.56 1,438.50 -1.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,012.15 +1.3%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,470.45 -1.2%
Cipla Ltd. Consolidated 2022-03 2,559.47 967.60 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,630.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,986.20 +0.4%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,782.90 +0.3%
Mankind Pharma Ltd. Standalone 2022-03 1,452.96 1,438.50 -1.9%

Sanjivani Paranteral Ltd. FAQ's

What is Sanjivani Paranteral share price?

Can I buy Sanjivani Paranteral shares now?

What is the Market Cap of Sanjivani Paranteral?

What are the key metrics to analyse Sanjivani Paranteral?

What is the 52 Week High and Low of Sanjivani Paranteral?

What is the trend of Sanjivani Paranteral share price?